Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Spotlight on Proffered Papers Session 1

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9
Characterization of antitumor activity of TAS6417, a novel EGFR-TKI targeting exon 20 insertions
Shinichi Hasako
TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies
Leila M Boustany
CytomX Therapeutics, South San Francisco, CA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2
Maurizio Scaltriti
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Loss of the lysosomal transporter SLC46A3 is a mechanism for innate and acquired resistance to non-cleavable maytansine and pyrrolobenzodiazepine-based antibody-drug conjugates
Krista Kinneer
MedImmune, Gaithersburg, MD, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
AG-120 (ivosidenib), a first-in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma
Vikram Deshpande
Massachusetts General Hospital, Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma
Susan Chi
Dana-Farber Cancer Institute, Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
First in human, dose escalation trial of the combination of dabrafenib, trametinib, and navitoclax in patients with BRAF mutant solid tumors
Ryan J Sullivan
Harvard Medical School/MGH, Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations
Alan Ho
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment
Clark C Chen
University of Minnesota, Minneapolis, MN, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 9 of 9